Network-1 Technologies IncNTIP
Price$1.60Intrinsic value$0.9342% below price

Qualitative Analysis

Business overview

Business Overview

Network-1 Technologies, Inc. (NYSE American: NTIP) is an intellectual property holding company specializing in the acquisition, development, licensing, and monetization of high-quality patent portfolios and proprietary technologies. The company works closely with inventors and patent owners to protect and commercialize intellectual property assets. Network-1 currently owns 119 U.S. patents and 15 international patents covering key technology domains, including Power over Ethernet (PoE) (Remote Power Patent), document stream operating systems (Mirror Worlds Patent Portfolio), embedded subscriber identification module (eSIM) technology for IoT and mobile devices (M2M/IoT Patent Portfolio), high-frequency trading (HFT Patent Portfolio), and smart home IoT device interoperability (Smart Home Patent Portfolio).

Research as of 20 Jun 2026

Strategic Initiatives

Growth programs, investments, and their expected impact

AI-assisted
Monetization of Active Patent PortfoliosGrowth

Transitioning focus from the expired Remote Power Patent to actively licensing and litigating other key portfolios, including M2M/IoT, HFT, Cox, and Smart Home patents.

Expected impact: Establishment of new recurring or one-time licensing and settlement revenues to replace the historical Remote Power Patent revenue.

Sign in / Sign up to read more
InvestmentOngoing litigation and professional fees, which rose to $1,415,000 in Q1 2026.
TimelineOngoing, with key trials scheduled for June 2027.
Strategic IP Acquisitions and InvestmentsInnovation

Evaluating and acquiring high-quality patent portfolios and making strategic investments in early-stage technology or clinical companies, utilizing the company's strong cash and marketable securities position.

Expected impact: Long-term capital appreciation and potential licensing opportunities.

Sign in / Sign up to read more
InvestmentSupported by $34.59 million in cash and marketable securities as of March 31, 2026.
TimelineContinuous evaluation.

Mergers, Acquisitions & Partnerships

Recent deals and strategic collaborations

AI-assisted

Strategic Partnerships

ILiAD Biotechnologies, Inc.Equity Investment & Strategic Partnership

Network-1 holds a 3.1% non-fully diluted equity stake in ILiAD, which is developing a lead vaccine candidate (BPZE1) for pertussis. This represents a key non-core technology investment with potential for significant capital appreciation.

Terms: Network-1 recorded a non-operating gain of $1,052,000 in Q1 2026 due to the remeasurement of its carrying value in ILiAD.

Sign in / Sign up to read more
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.